Nanoparticles News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

Accredited Duchenne Centers (ADC) Aims to Provide Uniform and Up-to-date Care for All People Living with Duchenne Muscular Dystrophy

Editorials July 3, 2025 0

The World Duchenne Organization (WDO) launched the international Accredited...

RGX-202 Gene Therapy Phase 3 Clinical Trial Begins

Research July 1, 2025 1

RGX-202, one of the alternative gene therapy candidates developed...

Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies

Research June 27, 2025 0

Entrada Therapeutics has officially launched clinical trials in Europe...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 5

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Nanoparticles

Must Read

Del-zota (EXPLORE44) Provides Nearly 30% Normal Dystrophin Production in Patients Amenable to Exon 44 Skipping

Belief BioMed BBM-D101 Gene Therapy Receives IND Clearance by National Medical Products Administration (NMPA)

Dr. Aravindhan Veerapandiyan, a neurologist at Arkansas Children’s Hospital, Reviews RGX-202 Gene Therapy Study